MedTrace Logo

A Dose-Escalation Study of RO7875913 in Healthy Participants

NCT07342114 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

RO7875913

Participants will receive RO7875913 as per the schedule described in the protocol.

DRUG

Placebo

Participants will receive placebo as per the schedule described in the protocol.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-11
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07342114 on ClinicalTrials.gov